Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference82 articles.
1. The ErbB signaling network: receptor heterodimerization in development and cancer;Olayioye;EMBO J,2000
2. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer;Baselga;J Clin Oncol,2005
3. Untangling the ErbB signalling network;Yarden;Nat Rev Mol Cell Biol,2001
4. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor;Tzahar;Mol Cell Biol,1996
5. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005
Cited by 136 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents;Current Medicinal Chemistry;2024-06-10
2. Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy;Expert Opinion on Pharmacotherapy;2024-03-23
3. A Review on the Synthesis and Anticancer Potentials of Imidazothiazole Derivatives;Mini-Reviews in Medicinal Chemistry;2023-09
4. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review;Current Oncology;2023-05-28
5. Revealing the roles of glycosphingolipid metabolism pathway in the development of keloid: a conjoint analysis of single-cell and machine learning;Frontiers in Immunology;2023-04-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3